ACE2 is considered a potential therapeutic target of RAS for the treatment of cardiovascular diseases due to its key role in limiting the vasoconstrictor action of AngII through its inactivation, and counteracting the actions of AngII through the formation of Ang (1–7), which is reported to have prevented left ventricular fibrosis and dysfunction at the Ang (1–7) or mas receptor [12]. The gene discussed is ACE2; the disease is cardiovascular disorder.